These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12534876)

  • 1. Adjuvant therapy for high-risk primary and resected metastatic melanoma.
    Hersey P
    Intern Med J; 2003; 33(1-2):33-43. PubMed ID: 12534876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate- and high-risk melanoma.
    Agarwala SS
    Curr Treat Options Oncol; 2002 Jun; 3(3):205-17. PubMed ID: 12057066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant IFN alpha2 therapy of melanoma.
    Kirkwood JM
    Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
    Kirkwood JM
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma: adjuvant therapy and other treatment options.
    Terando A; Sabel MS; Sondak VK
    Curr Treat Options Oncol; 2003 Jun; 4(3):187-99. PubMed ID: 12718796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does adjuvant vaccine therapy really have activity in malignant melanoma?
    Wheatley K; Ives NJ; Lorigan P
    J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569
    [No Abstract]   [Full Text] [Related]  

  • 14. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
    Agarwala S
    Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in management of melanoma.
    Hersey P
    Aust N Z J Med; 1999 Jun; 29(3):292-9. PubMed ID: 10868490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities.
    Otley CC; Zitelli JA
    Dermatol Surg; 2000 Mar; 26(3):177-80. PubMed ID: 10759789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
    Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ
    Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa.
    Mitchell MS; Darrah D; Stevenson L
    Cancer Invest; 2002; 20(5-6):759-68. PubMed ID: 12197233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.